A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study.-Reference-Cited by-同舟云学术

A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study.

Published:2008-05-20 Issue:15_suppl Volume:26 Page:LBA5504-LBA5504
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Monk B. J.,Sill M.,McMeekin D. S.,Cohn D. E.,Ramondetta L.,Boardman C. H.,Benda J.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2008.26.15_suppl.lba5504

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial;European Journal of Surgical Oncology (EJSO);2015-08

2. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer;Annals of Oncology;2011-06

3. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184;Gynecologic Oncology;2010-02

4. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group;Annals of Oncology;2010-01

5. Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer;British Journal of Cancer;2009-09-08